PortfoliosLab logoPortfoliosLab logo
IBB vs. IDNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

IBB vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Nasdaq Biotechnology ETF (IBB) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, IBB achieves a -0.68% return, which is significantly lower than IDNA's 10.31% return.


IBB

1D
1.97%
1M
-1.56%
YTD
-0.68%
6M
-2.57%
1Y
34.50%
3Y*
9.40%
5Y*
2.10%
10Y*
6.23%

IDNA

1D
0.73%
1M
-2.56%
YTD
10.31%
6M
8.52%
1Y
40.87%
3Y*
6.74%
5Y*
-8.42%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

IBB vs. IDNA - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
IBB
iShares Nasdaq Biotechnology ETF
-0.68%27.98%-2.41%3.76%-13.69%0.95%26.01%16.05%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
10.31%17.26%-0.72%-7.63%-42.28%-3.98%54.30%20.83%

Correlation

The correlation between IBB and IDNA is 0.89, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.89

Correlation (3Y)
Calculated over the trailing 3-year period

0.88

Correlation (5Y)
Calculated over the trailing 5-year period

0.90

Correlation (All Time)
Calculated using the full available price history since Jun 14, 2019

0.90

The correlation between IBB and IDNA has been stable across timeframes, ranging from 0.88 to 0.90 - a consistent structural relationship.

IBB vs. IDNA - Sectors Allocation Comparison


Sectors
IBB
IDNA

Healthcare

100.0%
97.8%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Financial Services

-

-

Industrials

-

0.4%

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

IBB
100.0%
IDNA
97.8%

Basic Materials

IBB

-

IDNA

-

Communication Services

IBB

-

IDNA

-

Consumer Cyclical

IBB

-

IDNA

-

Consumer Defensive

IBB

-

IDNA

-

Energy

IBB

-

IDNA

-

Financial Services

IBB

-

IDNA

-

Industrials

IBB

-

IDNA
0.4%

Real Estate

IBB

-

IDNA

-

Technology

IBB

-

IDNA

-

Utilities

IBB

-

IDNA

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

IBB vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IBB
IBB Risk / Return Rank: 5656
Overall Rank
IBB Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
IBB Sortino Ratio Rank: 5050
Sortino Ratio Rank
IBB Omega Ratio Rank: 4646
Omega Ratio Rank
IBB Calmar Ratio Rank: 7171
Calmar Ratio Rank
IBB Martin Ratio Rank: 6262
Martin Ratio Rank

IDNA
IDNA Risk / Return Rank: 5555
Overall Rank
IDNA Sharpe Ratio Rank: 4848
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 4949
Sortino Ratio Rank
IDNA Omega Ratio Rank: 4242
Omega Ratio Rank
IDNA Calmar Ratio Rank: 7676
Calmar Ratio Rank
IDNA Martin Ratio Rank: 6161
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IBB vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq Biotechnology ETF (IBB) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


IBBIDNADifference

Sharpe ratio

Return per unit of total volatility

1.74

1.68

+0.07

Sortino ratio

Return per unit of downside risk

2.50

2.44

+0.07

Omega ratio

Gain probability vs. loss probability

1.30

1.27

+0.02

Calmar ratio

Return relative to maximum drawdown

3.60

3.85

-0.25

Martin ratio

Return relative to average drawdown

11.43

10.98

+0.45

IBB vs. IDNA - Sharpe Ratio Comparison

The current IBB Sharpe Ratio is 1.74, which is comparable to the IDNA Sharpe Ratio of 1.68. The chart below compares the historical Sharpe Ratios of IBB and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


IBBIDNADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.74

1.68

+0.07

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.10

-0.30

+0.39

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.27

Sharpe Ratio (All Time)

Calculated using the full available price history

0.26

0.10

+0.16

Drawdowns

IBB vs. IDNA - Drawdown Comparison

The maximum IBB drawdown since its inception was -62.85%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for IBB and IDNA.


Loading charts...

Drawdown Indicators


IBBIDNADifference

Max Drawdown

Largest peak-to-trough decline

-62.85%

-68.26%

+5.41%

Max Drawdown (1Y)

Largest decline over 1 year

-9.63%

-10.66%

+1.03%

Max Drawdown (3Y)

Largest decline over 3 years

-24.85%

-29.73%

+4.88%

Max Drawdown (5Y)

Largest decline over 5 years

-39.82%

-68.26%

+28.44%

Max Drawdown (10Y)

Largest decline over 10 years

-39.82%

Current Drawdown

Current decline from peak

-5.64%

-45.61%

+39.97%

Average Drawdown

Average peak-to-trough decline

-21.18%

-36.24%

+15.06%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.03%

3.73%

-0.70%

Volatility

IBB vs. IDNA - Volatility Comparison

iShares Nasdaq Biotechnology ETF (IBB) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) have volatilities of 6.86% and 7.18%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


IBBIDNADifference

Volatility (1M)

Calculated over the trailing 1-month period

6.86%

7.18%

-0.32%

Volatility (6M)

Calculated over the trailing 6-month period

15.38%

17.98%

-2.60%

Volatility (1Y)

Calculated over the trailing 1-year period

19.89%

24.48%

-4.59%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

21.99%

28.42%

-6.43%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

23.22%

29.53%

-6.31%

IBB vs. IDNA - Expense Ratio Comparison

Both IBB and IDNA have an expense ratio of 0.47%.


Dividends

IBB vs. IDNA - Dividend Comparison

IBB's dividend yield for the trailing twelve months is around 0.23%, less than IDNA's 1.07% yield.


PositionTTM20252024202320222021202020192018201720162015
IBB
iShares Nasdaq Biotechnology ETF
0.23%0.23%0.29%0.26%0.31%0.21%0.21%0.33%0.20%0.30%0.19%0.03%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
1.07%1.18%0.98%1.04%0.54%0.70%0.26%0.80%0.00%0.00%0.00%0.00%

Frequently Asked Questions


IBB and IDNA have a correlation of 0.89, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IDNA has higher volatility (7.18%) compared to IBB (6.86%). In terms of maximum drawdown, IBB dropped -62.85% vs IDNA's -68.26%.

On 5-year performance, IBB leads with 2.10% vs -8.42% for IDNA. Both ETFs have the same 0.47% expense ratio. On volatility, IBB has been the lower-risk option at 6.86%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 5-year period, IBB has performed better with a 2.10% return vs -8.42%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

IBB and IDNA have the same expense ratio: 0.47% per year.

IDNA has the higher dividend yield at 1.07%, compared with 0.23% for IBB.

IBB tracks NASDAQ Biotechnology Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index.

IBB currently has the higher Sharpe Ratio (1.74 vs 1.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for IBB and IDNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer